MEDICAL ADVOCATES
NEW AND NEWSWORTHY
 Drug Archives   

 Back to New and Noteworthy


 Files identified with this icon are in Portable Document Format (PDF) and
require the Adobe Acrobat Reader


 
I    
Date Drug

Citation

    
 
Nov 29/30 Maraviroc (HIV/HCV Indications) Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
 
     
Nov 28 Darunavir Efficacy of a reduced dose of Darunavir/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.
     
Nov 27 Stribild Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis.
     
Nov 26 Nevirapine The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
     
Nov 25 Doravirine In Vitro Resistance Selection with Doravirine (MK-1439): a Novel Non-Nucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways.
     
Nov 24 Simeprevir Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
     
Nov 22/23 Boceprevir (HIV/HCV Indications)
 Telaprevir (HIV/HCV Indications)		 Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
 
     
Nov 21 Atazanavir Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
     
Nov 20 Boceprevir (HIV/HCV Indications)  Telaprevir (HIV/HCV Indications)
 Boceprevir (HCV Indications)   Telaprevir (HCV Indications)		 Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.

 
     
Nov 19 Daclatasvir Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition.

Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
     
Nov 18 Telaprevir Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
     
Nov 17 GSK1265744 Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.
     
Nov 15/16 Darunavir
Amprenavir		 Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics
Simulations.
     
Nov 14 Telaprevir Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with
telaprevir-based triple therapy.
     
Nov 13 Nevirapine The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.  
     
Nov 12 Atazanavir A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separateagents.
     
Nov 11 Tenofovir FULL-TEXT ARTICLE
Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study.
     
Nov 10 Dolutegravir Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
     
Nov 08/09 Raltegravir Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
     
Nov 07 Simeprevir Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
     
Nov 06 Sofosbuvir Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in US. Incarcerated populations: a cost-effectiveness analysis.
     
Nov 05 Boceprevir
 Telaprevir		 Drug-drug Interaction with Telaprevir or Boceprevir in Liver Transplant Patients: About Four Cases
     
Nov 04 Danoprevir A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
     
Nov 03 Darunavir Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.
     
Nov 01/02 Elvitegravir/Cobicistat
EmtricitabineTenofovir DF/Efavirenz/Emtricitabine
/Tenofovir DF		 Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.